αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia.
chronic lymphocytic leukemia
thyroid hormone
αvβ3 integrin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
19 Apr 2021
19 Apr 2021
Historique:
received:
25
02
2021
revised:
13
04
2021
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The thyroid hormones, T3 and T4, bind the αvβ3 integrin and activate phosphorylates ERK (pERK). These tumor-promoting actions were reported in a number of malignancies, but not in CLL. Primary cells from 22 CLL patients were verified for disease markers (CD5/CD19/CD23) and analyzed for αvβ3 by flow cytometry (FC), ImageStream, Western blots (WB), and immunohistochemistry (IHC) in archival bone marrow (BM, αvβ3 was detected on the membrane of circulating CLL cells and in the BM but not in the LN. T3 and T4 enhanced αvβ3 protein levels in primary CLL cells. Similarly, pERK and PCNA were rapidly induced in response to T3 and T4 exposure. αvβ3 integrin is expressed on primary CLL cells and is induced by thyroid hormones. We further suggest that the hormones are mitogenic in these cells, presumably via αvβ3-mediated signaling.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The thyroid hormones, T3 and T4, bind the αvβ3 integrin and activate phosphorylates ERK (pERK). These tumor-promoting actions were reported in a number of malignancies, but not in CLL.
METHODS
METHODS
Primary cells from 22 CLL patients were verified for disease markers (CD5/CD19/CD23) and analyzed for αvβ3 by flow cytometry (FC), ImageStream, Western blots (WB), and immunohistochemistry (IHC) in archival bone marrow (BM,
RESULTS
RESULTS
αvβ3 was detected on the membrane of circulating CLL cells and in the BM but not in the LN. T3 and T4 enhanced αvβ3 protein levels in primary CLL cells. Similarly, pERK and PCNA were rapidly induced in response to T3 and T4 exposure.
CONCLUSIONS
CONCLUSIONS
αvβ3 integrin is expressed on primary CLL cells and is induced by thyroid hormones. We further suggest that the hormones are mitogenic in these cells, presumably via αvβ3-mediated signaling.
Identifiants
pubmed: 33921634
pii: jcm10081766
doi: 10.3390/jcm10081766
pmc: PMC8073405
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Exp Hematol. 2001 Aug;29(8):993-1003
pubmed: 11495705
Adv Hematol. 2012;2012:138079
pubmed: 22400028
Isr Med Assoc J. 2004 Mar;6(3):147-51
pubmed: 15055269
Nat Rev Endocrinol. 2016 Feb;12(2):111-21
pubmed: 26668118
Haematologica. 2002 Aug;87(8):836-45
pubmed: 12161360
Nat Med. 1999 Nov;5(11):1277-84
pubmed: 10545994
Leukemia. 2000 Jan;14(1):34-9
pubmed: 10637474
Front Endocrinol (Lausanne). 2019 Feb 13;10:59
pubmed: 30814976
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
pubmed: 15459662
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
PLoS Comput Biol. 2011 Feb 03;7(2):e1001073
pubmed: 21304935
Contemp Oncol (Pozn). 2015;19(5):361-7
pubmed: 26793019
Blood. 1996 Dec 1;88(11):4259-64
pubmed: 8943862
Med Oncol. 2008;25(3):315-22
pubmed: 18183502
Cancer Res. 1957 May;17(4):325-8
pubmed: 13427015
Blood. 1993 May 15;81(10):2679-87
pubmed: 7683926
Cancer Res. 1960 Apr;20:373-6
pubmed: 14424312
Steroids. 2007 Feb;72(2):165-70
pubmed: 17166537
J Clin Invest. 2005 Mar;115(3):755-64
pubmed: 15711642
Leuk Lymphoma. 1993 Jun;10(3):209-16
pubmed: 8220119
Blood. 2005 Jun 15;105(12):4813-9
pubmed: 15731179
Blood. 1996 Jun 1;87(11):4780-8
pubmed: 8639849
Leuk Lymphoma. 1994 Jan;12(3-4):197-203
pubmed: 8167551
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii96-9
pubmed: 12379637
Endocr Relat Cancer. 2018 Jan;25(1):21-34
pubmed: 29018054
Mol Cancer Res. 2011 Oct;9(10):1385-94
pubmed: 21821675
J Clin Invest. 2012 Oct;122(10):3432-8
pubmed: 23023714
Leuk Res. 1991;15(7):609-18
pubmed: 1830631
Front Endocrinol (Lausanne). 2019 Feb 13;10:63
pubmed: 30814977
Endocr Relat Cancer. 2013 Mar 22;20(2):R19-29
pubmed: 23319493
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8156-61
pubmed: 9223331
Oncogene. 2016 Apr 14;35(15):1977-87
pubmed: 26165836